A retrospective, single-center study of primary letermovir prophylaxis as well as its effects on CS-CMVi, CMV end-organ disease, refractory or resistant CMV infections, and mortality in allogeneic HCT recipients
Latest Information Update: 13 Apr 2021
At a glance
- Drugs Letermovir (Primary) ; Letermovir (Primary) ; Ciclosporin; Cyclophosphamide; Ganciclovir
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
Most Recent Events
- 13 Apr 2021 New trial record
- 08 Apr 2021 Primary endpoint (development of refractory or resistant CMV infection after HCT) has been met.
- 08 Apr 2021 Results published in the Clinical Infectious Diseases